Hello, Thanks for signing up for MarketBeat Daily Ratings—we’re excited to have you on board. Every weekday, you’ll get a curated summary of new “Buy” and “Sell” ratings from Wall Street’s top-rated analysts, the latest stock news, and bonus investing content—all delivered straight to your inbox. You’re just two quick steps away from completing your sign-up: 1. Make sure our emails go to your inbox Gmail users:
Mobile: Tap the three dots (…) in the top right and select Move to Inbox or Move to Primary
Desktop: Click the folder icon at the top and select Move to Inbox or Primary Apple Mail users:
Tap our email address at the top (next to From: on mobile), then select Add to VIP Other providers:
Reply to this message and add newsletters@analystratings.net to your contacts 2. Confirm your subscription Click this link to confirm your subscription. This verifies your account and ensures you receive your newsletters without interruption instead of getting stuck in your spam filter. Confirm your subscription here. After you confirm, feel free to download our popular free report, "7 Stocks to Buy and Hold Forever" with this link. Thanks again for subscribing—we look forward to being part of your investing journey. 
Matthew Paulson
Founder and CEO, MarketBeat. P.S. If you didn’t mean to subscribe, no problem—you can unsubscribe here.
Exclusive Article 3 "Forever Stocks" to Hold When the Market Won't Sit StillWritten by Chris Markoch. Publication Date: 1/19/2026. 
Key Takeaways - Chevron provides long-term income potential through disciplined buybacks, a growing dividend, and exposure to global energy markets.
- Colgate-Palmolive delivers consistency with a diversified brand portfolio and more than six decades of annual dividend increases.
- Merck combines near-term cash flow from Keytruda with a late-stage oncology pipeline aimed at sustaining future growth.
With so much market volatility, it's a good time for investors to consider stocks they can hold for the long haul. These compounders don't need to make up a large portion of your portfolio, but they're ideal for investors who prefer to step away from their screens. Owning "forever stocks" is about more than chasing the next hot trade. It means building a portfolio around companies with durable competitive advantages, resilient cash flows and shareholder-friendly capital allocation policies. These are the businesses that can weather economic cycles, adapt to industry shifts and continue rewarding investors through dividends and long-term appreciation. There are 90 paper gold claims for every real ounce in COMEX vaults. Ninety promises, one ounce of metal. It's like musical chairs with 90 players and one chair. COMEX gold inventory dropped 25 percent last year alone as gold flows East to Shanghai, Mumbai, and Moscow. On March 31st, contract holders can demand delivery. When similar situations arose in the past, markets closed and rules changed. Paper holders got crushed while mining stock holders made fortunes. One stock sits at the center of this crisis. Get the full story on this opportunity now. Large-cap leaders with global footprints often fit this profile. They benefit from scale, strong brands and balance sheets that allow them to invest through downturns while returning capital to shareholders. While even the best companies can experience periods of underperformance, history shows patience is often rewarded when the underlying business remains sound. Chevron: Energy Income With Long-Term Staying Power Chevron Corp. (NYSE: CVX) is a large-cap among energy stocks. The integrated oil giant has stakes in the Permian Basin, several deep-water drilling projects and growing investments in renewable energy. CVX's stock is sensitive to oil-price swings, which helps explain why the stock produced a total return of just 5.1% over the past three years. Despite production near record levels, crude remains in the high $50s to low $60s, putting pressure on earnings. That said, over the last 10 years CVX has delivered a total return of more than 200%. The company has a history of share buybacks and a reliable, growing dividend; the yield was 4.12% at the time of writing. Perhaps more telling is the annualized payout of $6.84 per share and Chevron's status as a dividend aristocrat, with 38 consecutive years of dividend increases. Colgate-Palmolive: A Dividend King Built for Consistency Colgate-Palmolive Co. (NYSE: CL) is a leading name among consumer staples stocks. With a deep portfolio of household brands sold around the world, the bullish case for CL echoes Peter Lynch's advice to "own what you know." You don't need an advanced degree to appreciate the stable, long-term demand for its products. Investors who bought in recent years may have needed a strong stomach: this "forever" stock returned roughly 15% over the past five years, including the company's dividend, which yields about 2.47%. Over longer time spans, however, CL has been a reliable wealth compounder thanks to its status as a dividend king. The company has raised its dividend for 63 consecutive years. And at around 22x earnings, the stock looks reasonably valued relative to its own history and the broader market. Merck: Pipeline-Driven Growth Beyond Keytruda Merck & Co. (NYSE: MRK) took investors on a roller coaster in 2025, falling to about $72—roughly 45% below its June 2024 all-time high. Like the other names here, MRK has been a challenging hold over the past three years, delivering a total return of just over 10%. Merck depends on its blockbuster Keytruda for just under half of its revenue. Keytruda won't face its patent cliff until 2028, but institutional investors are already focused on how Merck will replace that revenue when the time comes. The situation resembles what AbbVie Inc. (NYSE: ABBV) faced with Humira; AbbVie successfully offset that loss, and Merck must prove it can do the same. There is reason for optimism in Merck's pipeline. The company is pursuing additional indications for Keytruda and has 16 oncology drugs in late-stage trials. Approval of even one or two of those candidates in the next couple of years could materially address the potential revenue shortfall.
| 
0 Response to "We're excited to have you on board"
Post a Comment